Skip to content

In the BioHarmony Drug Report Database

Palivizumab

Synagis (palivizumab) is an antibody pharmaceutical. Palivizumab was first approved as Synagis on 1998-06-19. It is used to treat respiratory syncytial virus infections in the USA. It has been approved in Europe to treat respiratory syncytial virus infections.
Trade Name Synagis
Common Name Palivizumab
Indication respiratory syncytial virus infections
Drug Class Monoclonal antibodies: humanized, antiviral indications
Palivizumab
Get full access now